We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
151
DELISTED
Chimerix, Inc.
CMRX
$156K 0.03%
+178,229
New +$169K
BKHAU
152
Black Hawk Acquisition Corp Units
BKHAU
$85.8M
$155K 0.03%
15,000
– –
ARWR icon
153
Arrowhead Research
ARWR
$12.6B
$153K 0.03%
5,900
+5,300
+883% +$130K
RLMD icon
154
Relmada Therapeutics
RLMD
$574M
$152K 0.03%
50,601
+50,000
+8,319% +$181K
VYGR icon
155
Voyager Therapeutics
VYGR
$189M
$147K 0.03%
18,634
-72,900
-80% -$611K
KALV
156
DELISTED
KalVista Pharmaceuticals
KALV
$142K 0.03%
12,020
+2,020
+20% +$23.6K
NXTC icon
157
NextCure
NXTC
$23.5M
$142K 0.03%
7,418
+3,833
+107% +$74.5K
KTTA icon
158
Pasithea Therapeutics
KTTA
$15.4M
$140K 0.03%
27,696
– –
BOLT icon
159
Bolt Biotherapeutics
BOLT
$7.59M
$139K 0.03%
9,300
+9,050
+3,620% +$179K
FULC icon
160
CALL
Fulcrum Therapeutics
FULC
$290M
$124K 0.02%
+20,000
New +$152K
PRTA icon
161
Prothena Corp
PRTA
$444M
$124K 0.02%
5,988
– –
EGRX
162
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$123K 0.02%
+22,000
New +$95.8K
PLRX icon
163
Pliant Therapeutics
PLRX
$65M
$108K 0.02%
+10,000
New +$129K
VRDN icon
164
Viridian Therapeutics
VRDN
$2.3B
$104K 0.02%
8,000
+5,450
+214% +$75.4K
TERN
165
DELISTED
Terns Pharmaceuticals
TERN
$102K 0.02%
15,000
+10,000
+200% +$60.6K
SRRK icon
166
Scholar Rock
SRRK
$5.73B
$100K 0.02%
+12,000
New +$147K
TGTX icon
167
TG Therapeutics
TGTX
$7.46B
$99.4K 0.02%
5,589
+1,228
+28% +$19.6K
EQ icon
168
Equillium
EQ
$143M
$97.6K 0.02%
140,775
-58,000
-29% -$82.8K
CAPR icon
169
PUT
Capricor Therapeutics
CAPR
$241M
$97.3K 0.02%
+20,400
New +$114K
KCGI
170
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
$94.2K 0.02%
8,500
-500
-6% -$5.5K
BBIO icon
171
CALL
BridgeBio Pharma
BBIO
$16.1B
$93.7K 0.02%
+3,700
New +$101K
BLCO icon
172
Bausch + Lomb
BLCO
$5.96B
$92.9K 0.02%
6,400
+1,100
+21% +$16.5K
AQN icon
173
Algonquin Power & Utilities
AQN
$4.46B
$87.9K 0.02%
15,000
-22,000
-59% -$136K
FBRX icon
174
Forte Biosciences
FBRX
$1.57B
$85.5K 0.02%
6,370
-450
-7% -$7.27K
PMVP icon
175
PMV Pharmaceuticals
PMVP
$62.4M
$81K 0.02%
50,000
+40,000
+400% +$72.1K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.